raltegravir

Type: Keyphrase
Name: raltegravir
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

High Rate of NPEP Completion, Good Safety, With Raltegravir Plus TDF/FTC

ID WeekOct 8-12 2014Philadelphia IDWeek 2014, October 8-12, 2014, PhiladelphiaMark MascoliniMore than 4 in 5 people in a Houston study completed nonoccupational postexposure prophylaxis (NPEP) with raltegravir plus tenofovir/emtricitabine (TDF/FTC) [1]. ... [Published National AIDS Treatment Advocacy Project - Oct 17 2014]
First reported Oct 15 2014 - Updated Oct 16 2014 - 2 reports

A 28-Day High-Dose Safety and Pharmacokinetics Study of Raltegravir in Healthy Subjects

ID WeekOct 8-12 2014Philadelphia Reported by Jules LevinIDSA 2014, October 8-12, 2014, PhiladelphiaKrishna R1, Rizk ML1, Schulz V1, Bruggencate-Broeders ten J1, Liu R1, Larson P1, and Farha KA21Merck Research Laboratories, Merck & Co., Inc., Whitehouse ... [Published National AIDS Treatment Advocacy Project - Oct 16 2014]
First reported Oct 11 2014 - Updated Oct 11 2014 - 1 reports

Gender, Depression, Heart and Liver Disease Affect First-Line ART Choice in US

ID WeekOct 8-12 2014Philadelphia IDWeek 2014, October 8-12, 2014, PhiladelphiaMark MascoliniWomen and people with depression or liver disease were less likely to start antiretroviral therapy (ART) with a nonnucleoside (NNRTI) in a 1215-person 8-clinic ... [Published National AIDS Treatment Advocacy Project - Oct 11 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

HIV: Non-Efavirenz Regimens Effective in Initial Treatment

Several regimens that exclude efavirenz have similar efficacy in the initial treatment of HIV, according to results from a phase 3 AIDS Clinical Trials Group randomized controlled trial published online October 6 in the Annals of Internal Medicine . The ... [Published General Medicine eJournal - Oct 10 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

HIV Attachment Inhibitor BMS-663068 Compares Well to Boosted Atazanavir at 24 Weeks

In its bid to become the first approved member of a new class of HIV medications, the attachment inhibitor BMS-663068, also known as "068" or fostemsavir, showed similar efficacy to ritonavir (Norvir)-boosted atazanavir (Reyataz) in Phase 2b study results ... [Published The Body - Oct 10 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

Efavirenz-free regimens prove effective for initial treatment of HIV

Ratings require JavaScript to be enabled.Patients who cannot take efavirenz for initial treatment of HIV have effective options, according to an article being published in Annals of Internal Medicine.Efavirenz is a component of many effective antiretroviral ... [Published Medical News Today - Oct 08 2014]
First reported Oct 06 2014 - Updated Oct 07 2014 - 1 reports

Effective treatments available for HIV patients not eligible for efavirenz regimens

17:00, HIV & AIDSA new national clinical trial found HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy. The finding is important for patients who are not eligible for treatment with efavirenz, including ... [Published Medical Xpress - Oct 06 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in ...

Ongoing HIV-1 replication in lymphoid cells is one explanation of the persistence of HIV-1 reservoirs despite highly active antiretroviral therapy (cART). We tested the potential of cART intensification by Maraviroc plus Raltegravir to decrease proviral ... [Published 7thSpace - Oct 07 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

Every patient received emtricitabine, 200 mg/d, plus tenofovir disoproxil fumarate, 300 mg/d. In addition, each patient was randomly assigned to receive either atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, ... [Published Annals of Internal Medicine - Oct 07 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 1 reports

New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ...

If you're an ID doc based in the U.S., you probably received notice last week that two new HIV drugs were approved -- cobicistat and elvitegravir .And if you're wondering what the big deal is, welcome to the club. In fact, the Canadians beat us to the ... [Published The Body - Sep 29 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 3 reports

Elvitegravir / Vitekta FDA Approval

On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ... [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
First reported Jun 05 2014 - Updated Jun 06 2014 - 4 reports

Merck begins patient enrollment in Phase III trial of HIV-drug Isentress

Merck has started patient enrollment in its global Phase III clinical trial 'ONCEMRK', which is evaluating a once-daily investigational formulation of Isentress (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve ... [Published PBR - News - Jun 06 2014]

Quotes

...They proposed that "efforts on prevention strategies need to continue to focus on the high-risk groups, particularly those with low adherence to treatment completion such as African Americans."
The brand name is "Harvoni," which sounds a bit like an exotic offering on a menu that you need to ask your waiter to explain -- "Ancho chile-rubbed Niman Ranch pork chop roasted in soy, ginger, and sesame, served with pan-sauted garlic kale, and garnished with corn and pinapple-harvoni salsa."
http://www.natap.org/2013/ICAAC/ICAAC_62.htm....... "We report three cases in which raltegravir was used late in pregnancy to rapidly reduce maternal HIV-1 viral load (Roche Taqman 2.0 assay), in women with multidrug resistant virus." [PDF]
"As more choices for HIV therapy become available," the CNICS investigators suggested, "factors that impact initial regimen selection will likely become even more heterogeneous over time."

More Content

All (46) | News (36) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
High Rate of NPEP Completion, Good Safety, With... [Published National AIDS Treatment Advocacy Project - Oct 17 2014]
A 28-Day High-Dose Safety and Pharmacokinetics ... [Published National AIDS Treatment Advocacy Project - Oct 16 2014]
Approval of Sofosbuvir/Ledipasvir Was Expected,... [Published The Body - Oct 15 2014]
Safety, Tolerability, and Antiretroviral Activi... [Published National AIDS Treatment Advocacy Project - Oct 15 2014]
Hypoxia Induces Dysregulation of Lipid Metaboli... [Published Sexual Development - Oct 14 2014]
Gender, Depression, Heart and Liver Disease Aff... [Published National AIDS Treatment Advocacy Project - Oct 11 2014]
HIV: Non-Efavirenz Regimens Effective in Initia... [Published General Medicine eJournal - Oct 10 2014]
HIV Attachment Inhibitor BMS-663068 Compares We... [Published The Body - Oct 10 2014]
Efavirenz-free regimens prove effective for ini... [Published Medical News Today - Oct 08 2014]
Failure of combined antiretroviral therapy inte... [Published 7thSpace - Oct 07 2014]
Nonnucleoside Reverse Transcriptase Inhibitor–S... [Published Annals of Internal Medicine - Oct 07 2014]
News from Annals of Internal Medicine tip sheet... [Published EurekAlert! - Oct 06 2014]
Effective treatments available for HIV patients... [Published Medical Xpress - Oct 06 2014]
Einstein & Montefiore Investigators Present Res... [Published Newswise - Oct 01 2014]
FDA approves two new doses of elvitegravir, in ... [Published Project Inform - Sep 30 2014]
New FDA HIV Drug Approvals Unlikely to Have Muc... [Published The Body - Sep 29 2014]
Elvitegravir / Vitekta FDA Approval [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
Persistence of Virus Reservoirs in ART-Treated ... [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
For HIV/HCV Coinfected Patients, 3D With Ribavi... [Published The Body - Sep 26 2014]
Gilead receives approval for two HIV-1 cocktail... [Published Drugtopics.com - Sep 26 2014]
FDA Approves 2 HIV-1 Cocktail Drugs [Published Diabetes Care - Sep 25 2014]
Tybost (Cobicistat) and Vitekta (Elvitegravir) ... [Published The Body - Sep 25 2014]
Could an Integrase Inhibitor Have Prevented One... [Published The Body - Sep 19 2014]
HIV and the SANDF: Interview with Dr Heila Redpath [Published News24 - Sep 19 2014]
Use of Third Line Antiretroviral Therapy in Lat... [Published Plosone.org - Sep 15 2014]
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - Sep 15 2014]
Cipla enters into a licensing agreement with Gi... [Published India Infoline - Sep 15 2014]
Health Insurance Companies Are the Biggest Impe... [Published The Body - Sep 12 2014]
Bone Mineral Density Over 96 Weeks in Adults Fa... [Published JAIDS - Sep 11 2014]
Improved Single Copy Assays for Quantification ... [Published National AIDS Treatment Advocacy Project - Sep 10 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - Sep 15 2014]
Can we reduce human endogenous retroviruses or HERVs with a treatment? #MSBlog #MSResearch "Just arrived back from Boston; exhausted physically, mentally and no doubt more to come with jet-lag. One of the highlights for me at ECTRIMS was the interest ...
[Department of Error] Department of Error [Published The Lancet - Sep 05 2014]
Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735–43—The ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. ...
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.